Armata Pharmaceuticals announced that the U.S. FDA granted Breakthrough Therapy designation to AP-SA02 for the adjunct treatment of complicated bacteremia caused by methicillin-sensitive or methicillin-resistant Staphylococcus aureus. This designation, driven by Phase 2 data showing superior clinical cure rates compared to placebo plus best available antibiotic therapy, aims to expedite review and development. The company plans to initiate a Phase 3 superiority study in the second half of 2026. Armata Pharmaceuticals is a late-stage biotechnology company developing bacteriophage therapeutics for antibiotic-resistant bacterial infections.
